KTRA News & Events

Kintara Therapeutics (KTRA) announced that its board of directors has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger with TuHURA, the company stated. Following the closing of the merger, the combined company's total outstanding common stock is expected to be approximately 42.0M shares. TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda in first line treatment for advanced Merkel Cell Carcinoma.

Kintara Therapeutics (KTRA) announced that its board of directors has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger with TuHURA, the company stated. Following the closing of the merger, the combined company's total outstanding common stock is expected to be approximately 42.0M shares. TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda in first line treatment for advanced Merkel Cell Carcinoma.

Kintara Therapeutics announced a record date of October 17 for the issuance of Contingent Value Rights - CVRs - to stockholders of record of Kintara as of the Record Date. In April, Kintara entered into a definitive merger agreement (with TuHURA Biosciences, a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Kintara's wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary. The proposed Merger is expected to close on October 18. The Record Date is subject to change based on the final Closing Date. Kintara will issue a number of CVRs to Kintara stockholders as of the Record Date entitling the holders thereof to an aggregate of 53,897,125 shares of Kintara's common stock upon the achievement of certain milestones. Kintara stockholders will receive one CVR per share of Kintara common stock each respectively owned. The CVRs will be issued immediately prior to the proposed reverse stock split and closing of the proposed Merger. Kintara expects to effect a reverse stock split at a ratio of 1-for-35 immediately prior to the consummation of the proposed Merger.